Apolipoprotein E e4 Allele Is Associated with Subjective Cognitive Decline: A Meta-Analysis

Introduction: Possession of one or two e4 alleles of the apolipoprotein E (APOE) gene is associated with cognitive decline and dementia risk. Some evidence suggests that physical activity may benefit carriers of the e4 allele differently.Method: We conducted a systematic review and meta-analysis of studies which assessed APOE differences in the association between physical activity and: lipid profile, Alzheimer’s disease pathology, brain structure and brain function in healthy adults. Searches were carried out in PubMed, SCOPUS, Web of Science and PsycInfo.Results: Thirty studies were included from 4896 papers screened. Carriers of the e4 allele gained the same benefit from physical activity as non-carriers on most outcomes. For brain activation, e4 carriers appeared to gain a greater benefit from physical activity in activation and functional connectivity compared to non-carriers. Post hoc analysis identified possible compensatory mechanisms allowing e4 carriers to maintain cognitive function.Discussion: Though there is evidence suggesting physical activity may benefit e4 carriers differently compared to non-carriers, this may vary by the specific brain health outcome, perhaps limited to brain activation. Further research is required to confirm these findings and elucidate the mechanisms.

Download Full-text

Interactive Effects of Apolipoprotein E ε4 and Triiodothyronine on Memory Performance in Patients With Subjective Cognitive Decline

Frontiers in Medicine ◽

10.3389/fmed.2020.00298 ◽

2020 ◽

Vol 7 ◽

Author(s):

Jin San Lee ◽

Yunsoo Soh ◽

Hyug-Gi Kim ◽

Kyung Mi Lee ◽

Young Nam Kwon ◽

...

Keyword(s):

Cognitive Decline ◽

Apolipoprotein E ◽

Memory Performance ◽

Interactive Effects ◽

Subjective Cognitive Decline

Download Full-text

Affective symptoms and risk of progression to mild cognitive impairment or dementia in subjective cognitive decline: A systematic review and meta-analysis

Ageing Research Reviews ◽

10.1016/j.arr.2021.101419 ◽

2021 ◽

pp. 101419

Author(s):

Roopal Desai ◽

Tim Whitfield ◽

Glorianne Said ◽

Amber John ◽

Rob Saunders ◽

...

Keyword(s):

Systematic Review ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Cognitive Decline ◽

Meta Analysis ◽

Subjective Cognitive Decline ◽

Affective Symptoms ◽

Risk Of Progression

Download Full-text

Association of Subjective Cognitive Decline with Risk of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of Prospective Longitudinal Studies

Journal of Prevention of Alzheimer's Disease ◽

10.14283/jpad.2021.27 ◽

2021 ◽

pp. 1-9

Author(s):

X.-T. Wang ◽

Z.-T. Wang ◽

H.-Y. Hu ◽

Y. Qu ◽

M. Wang ◽

...

Keyword(s):

Systematic Review ◽

Cognitive Impairment ◽

Cognitive Decline ◽

Meta Analysis ◽

Cognitive Disorders ◽

Excess Risk ◽

Subjective Cognitive Decline ◽

Healthy Individuals ◽

Subgroup Analyses ◽

Fold Excess

Background: Subjective cognitive decline (SCD) as an early pathological manifestation of brain aging has become more prevalent among older adults. Objectives: We aimed to investigate the associations of subjective cognitive decline (SCD) with the combined risk of cognitive impairment and dementia. Design: We performed a systematic review and meta-analysis via searching Embase, PubMed and Cochrane electronic databases from January 1 st 1970 to June 4th, 2020. Setting: Prospective cohort studies Participants: Healthy individuals were recruited from community, clinics and population. Measurements: Healthy individuals with SCD were classified into exposure groups, while those without were considered as the reference group. Adjusted relative risks (RR) were estimated in a random-effects model. Both primary and subgroup analyses were conducted. Results: Of 28,895 identified studies, 21 studies containing 22 cohorts were eligible for inclusion in the meta-analysis. SCD increased the risk of subsequent cognitive disorders (RR=2.12, 95% confidence intervals [CI] =1.75-2.58, I2=87%, P<0.01). To be specific, SCD conferred a 2.29-fold excess risk for cognitive impairment (RR=2.29, 95% CI=1.66-3.17, I2=83%, P<0.01) and a 2.16-fold excess risk for dementia (RR=2.16, 95% CI=1.63-2.86, I2=81%, P<0.01). In subgroup analyses, participants with SCD in the subgroup of 65-75 years old, long-education (>15 years) subgroup and subgroup of clinics showed a higher risk of developing objective cognitive disorders. Conclusions: SCD is associated with an increased combined risk of cognitive impairment and incident dementia and should be considered a risk factor for objective cognitive disorders.

Download Full-text

Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations

Neuropsychology Review ◽

10.1007/s11065-017-9342-8 ◽

2017 ◽

Vol 27 (3) ◽

pp. 245-257 ◽

Cited By ~ 34

Author(s):

Colette M. Smart ◽

◽

Justin E. Karr ◽

Corson N. Areshenkoff ◽

Laura A. Rabin ◽

...

Keyword(s):

Systematic Review ◽

Older Adults ◽

Cognitive Decline ◽

Meta Analysis ◽

Subjective Cognitive Decline

Download Full-text

A systematic review and network meta‐analysis of interventions for subjective cognitive decline

Alzheimer s & Dementia Translational Research & Clinical Interventions ◽

10.1002/trc2.12180 ◽

2021 ◽

Vol 7 (1) ◽

Author(s):

Mandy Roheger ◽

Xenia‐Serena Hennersdorf ◽

Steffen Riemann ◽

Agnes Flöel ◽

Marcus Meinzer

Keyword(s):

Systematic Review ◽

Cognitive Decline ◽

Meta Analysis ◽

Subjective Cognitive Decline

Download Full-text

Gender-specific design and effectiveness of non-pharmacological interventions against cognitive decline and dementia–protocol for a systematic review and meta-analysis

PLoS ONE ◽

10.1371/journal.pone.0256826 ◽

2021 ◽

Vol 16 (8) ◽

pp. e0256826

Author(s):

Andrea E. Zuelke ◽

Steffi G. Riedel-Heller ◽

Felix Wittmann ◽

Alexander Pabst ◽

Susanne Roehr ◽

...

Keyword(s):

Systematic Review ◽

Cognitive Decline ◽

Meta Analysis ◽

Grey Literature ◽

Primary Data ◽

Subjective Cognitive Decline ◽

Cochrane Central Register ◽

Specific Design ◽

Meta Analyses ◽

Gender Specific

Introduction Dementia is a public health priority with projected increases in the number of people living with dementia worldwide. Prevention constitutes a promising strategy to counter the dementia epidemic, and an increasing number of lifestyle interventions has been launched aiming at reducing risk of cognitive decline and dementia. Gender differences regarding various modifiable risk factors for dementia have been reported, however, evidence on gender-specific design and effectiveness of lifestyle trials is lacking. Therefore, we aim to systematically review evidence on gender-specific design and effectiveness of trials targeting cognitive decline and dementia. Methods and analysis We will conduct a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases MEDLINE (PubMed interface), PsycINFO, Web of Science Core Collection, Cochrane Central Register of Controlled Trials (CENTRAL) and ALOIS will be searched for eligible studies using a predefined strategy, complemented by searches in clinical trials registers and Google for grey literature. Studies assessing cognitive function (overall measure or specific subdomains) as outcome in dementia-free adults will be included, with analyses stratified by level of cognitive functioning at baseline: a) cognitively healthy b) subjective cognitive decline 3) mild cognitive impairment. Two reviewers will independently evaluate eligible studies, extract data and determine methodological quality using the Scottish Intercollegiate Guidelines Network (SIGN)-criteria. If sufficient data with regards to quality and quantity are available, a meta-analysis will be conducted. Ethics and dissemination No ethical approval will be required as no primary data will be collected. PROSPERO registration number CRD42021235281.

Download Full-text

Auditory electrophysiological assessments of Alzheimer’s disease and preclinical stages: protocol for a systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2019-033308 ◽

2020 ◽

Vol 10 (7) ◽

pp. e033308

Author(s):

Hadeel Y Tarawneh ◽

Wilhelmina H A M Mulders ◽

Hamid R Sohrabi ◽

Ralph N Martins ◽

Dona M P Jayakody

Keyword(s):

Systematic Review ◽

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Cognitive Decline ◽

Meta Analysis ◽

Subjective Cognitive Decline ◽

Medical Subject Headings ◽

Preclinical Ad ◽

Populations At Risk ◽

Auditory Functions

IntroductionInvestigating auditory functions in populations at risk of developing Alzheimer’s disease (AD) using auditory neurophysiological measurements can potentially identify a crucial and sensitive diagnostic window of opportunity in preclinical AD. Auditory electrophysiological assessments have gained interest as possible tools for early diagnosis of AD. This paper outlines the protocol that will be used to systematically review the published literature currently available on auditory electrophysiological assessments that have been used to assess the auditory functions of adults over the age of 60 years diagnosed with AD or its preclinical stages.Methods and analysisAll full-length peer-reviewed publications of original data that use auditory electrophysiological assessments in AD and its preclinical stages (subjective cognitive decline (SCD) and mild cognitive impairment (MCI)) will be considered in this review. The search will be performed on major electronic databases (Ovid MEDLINE, Ovid Embase, PsycINFO, PubMed, Scopus and CINAHL Plus) using keywords alone or in combination with Medical Subject Headings divided into two domains; (i) auditory tests and (ii) AD. The database search will be conducted on the 7th of May 2019. Data analysis will be completed and reported in the full review. A random effects meta-analysis will also be conducted using the Comprehensive Meta-Analysis software, V.3. This review will describe which auditory electrophysiological tests have been found to be useful in assessing the auditory function in cognitively impaired adults (MCI and AD) or adults with serious complaints about their cognition (SCD). This review will also identify and describe which auditory electrophysiological test demonstrates the most sensitivity in differentiating people at different stages of cognitive decline.Ethics and disseminationThis systematic review focusses on analysing already available literature. Therefore, there will be no requirement for ethical approval. The systematic review findings will be disseminated through peer-reviewed publication as well as relevant media platforms, for example, conferences.Systematic review registrationPROSPERO CRD42019133553.

Download Full-text

Potential Sex-Specific Effects of Apolipoprotein E ɛ4 on Cognitive Decline in Early Parkinson’s Disease

Journal of Parkinson s Disease ◽

10.3233/jpd-202288 ◽

2020 ◽

pp. 1-9

Author(s):

Ryul Kim ◽

Sangmin Park ◽

Dallah Yoo ◽

Young Ju Suh ◽

Jin-Sun Jun ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Cognitive Decline ◽

Apolipoprotein E ◽

De Novo ◽

Sensitivity Analyses ◽

Specific Effects ◽

E4 Allele ◽

Generalized Linear Mixed Effects

Background/Objective: To compare the longitudinal trajectories of cognition according to the presence of the apolipoprotein E (APOE) ɛ4 allele in male and female Parkinson’s disease (PD) patients. Methods: This study included a total of 361 patients with recently diagnosed de novo PD (mean age [standard deviation], 61.4 [9.8] years). The patients were classified into the following groups: APOE ɛ4 + /M (n = 65), APOE ɛ4-/M (n = 173), APOE ɛ4 + /F (n = 25), and APOE ɛ4-/F (n = 98). Cognitive decline was assessed annually over 5 years of follow-up using the Montreal Cognitive Assessment (MoCA). To assess the sex-specific impacts of the APOE ɛ4 status on cognitive decline, we used generalized linear mixed effects (GLME) models separately for men, women, and the two sexes combined. Results: In the sex-stratified GLME models adjusted for covariates, the interaction results showed that the males with APOE ɛ4 had a steeper rate of cognitive decline than those without APOE ɛ4. In contrast, there was no significant interaction between APOE ɛ4 and time on longitudinal MoCA performance in the females. The main effect of APOE ɛ4 on the change in the MoCA score was not significant for either men or women. When the data from both men and women were used, the APOE ɛ4 + /M group exhibited a steeper rate of cognitive decline than did the APOE ɛ4 + /F and APOE ɛ4-/F groups. These results were consistent with those of sensitivity analyses. Conclusion: Sex may be considered when APOE ɛ4-related vulnerability to early cognitive decline is evaluated in PD patients.

Download Full-text